GU Cancers 2021 | Clinical outcomes and genomic correlates of African Americans with mCSPC
Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, discusses the results of a multi-institutional evaluation of the clinical outcomes and genomic correlates of African American men with metastatic castration-sensitive prostate cancer (mCSPC). The primary objective of this study is to describe baseline disease characteristics through analysis of demographic and genetic data of African American men with hormone-sensitive disease being offered treatment for mCSPC. Dr Barata describes common germline and somatic alterations in the genomic profiles of African American patients and explains that despite these treatment outcomes suggest racial differences, indicating that further research is needed to address disparity in prostate cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Pedro Barata, MD, MSc, has served in a consulting or advisory role for Bayer, Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai, Caris Life Sciences, Clovis, and Dendreon; and has received institutional research funding from Blue Earth Diagnostics, AstraZeneca and Merck.
